longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Exagen (XGN) Receives a Buy from Roth MKM

Tip Ranks
Sep 22, 2026 at 01:15 PM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Roth MKM analyst Max Masucci maintained a Buy rating on Exagen today and set a price target of $11.00. Masucci covers the Healthcare sector, focusing on stocks such as Castle Biosciences, Exagen, and Biodesix. According to TipRanks, Masucci has an average return of 10.2% and a 44.58% success rate on recommended stocks. In a report released on September 11, B. Riley Securities also maintained a Buy rating on the stock with a $12.00 price target.

Roth MKM analyst Max Masucci maintained a Buy rating on Exagen today and set a price target of $11.00.

Masucci covers the Healthcare sector, focusing on stocks such as Castle Biosciences, Exagen, and Biodesix. According to TipRanks, Masucci has an average return of 10.2% and a 44.58% success rate on recommended stocks.

In a report released on September 11, B. Riley Securities also maintained a Buy rating on the stock with a $12.00 price target.

Login to unlock449characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Related Stocks

Exagen

Exagen

USXGN

-0.23%

Castle Biosciences

Castle Biosciences

USCSTL

Biodesix

Biodesix

USBDSX

LongbridgeAI